<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03070197</url>
  </required_header>
  <id_info>
    <org_study_id>2016-6315</org_study_id>
    <secondary_id>5U01HL131003-02</secondary_id>
    <nct_id>NCT03070197</nct_id>
  </id_info>
  <brief_title>Genomic Basis of Neurodevelopmental and Brain Outcomes in Congenital Heart Disease (CHD Brain and Genes)</brief_title>
  <official_title>Genomic Basis of Neurodevelopmental and Brain Outcomes in Congenital Heart Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Hospital Medical Center, Cincinnati</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Approximately 400 Congenital heart disease patients will participate in the research study&#xD;
      which will include one or more research visits for neurodevelopmental testing, brain MRI, and&#xD;
      collection of medical history including previously collected genetic sequencing results. The&#xD;
      investigators will explore the association between genetic variants, neurodevelopmental&#xD;
      deficits, and brain MRI endophenotype. Analyses will compare groups with and without&#xD;
      deleterious de novo mutations.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 18, 2017</start_date>
  <completion_date type="Actual">June 29, 2020</completion_date>
  <primary_completion_date type="Actual">June 29, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Neurodevelopment and behavioral health assessment</measure>
    <time_frame>Day 1</time_frame>
    <description>The investigators will compare groups with respect to achievement, IQ, learning disability, specific neuropsychological domains (e.g., memory, attention, executive functions, and visual-spatial/motor integration), adaptive function, behavior, social cognition and symptoms of autism spectrum disorder, and quality of life. The primary study outcome for this aim will be the WRAT4 composite score.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Abnormalities in brain structure and microstructure on MRI</measure>
    <time_frame>Day 1</time_frame>
    <description>The investigators will compare the groups with respect to measured and derived parameters including, but not limited to, 1) regional volumetric and cortical thickness, 2) regional surface metrics, 3) voxel-based DTI eigenvectors and apparent diffusion coefficient (ADC) values, and resting state principal component analysis</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">196</enrollment>
  <condition>Heart Disease Congenital</condition>
  <arm_group>
    <arm_group_label>Case/CHD with deleterious mutations</arm_group_label>
    <description>Participants with CHD with damaging de novo mutations or stringently defined deleterious missense mutations) on whole exome sequencing or whole genome sequencing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control/CHD without deleterious mutations</arm_group_label>
    <description>Participants with CHD without damaging de novo mutations or stringently defined deleterious missense mutations) on whole exome sequencing or whole genome sequencing</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Exposure of interest: Brain MRI</intervention_name>
    <description>Brain MRI will be conducted in all participants</description>
    <arm_group_label>Case/CHD with deleterious mutations</arm_group_label>
    <arm_group_label>Control/CHD without deleterious mutations</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Exposure of interest: neurodevelopmental assessments</intervention_name>
    <description>neurodevelopmental testing will be conducted in all participants.</description>
    <arm_group_label>Case/CHD with deleterious mutations</arm_group_label>
    <arm_group_label>Control/CHD without deleterious mutations</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Congenital heart disease patients aged 8 years and older with prior whole exome sequencing&#xD;
        or whole genome sequencing results&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects in whom whole exome sequencing or whole genome sequencing has already been&#xD;
             performed, either during the CHD GENES study or, for new centers (Utah or&#xD;
             USCF/Stanford), after trios in existing biobanks undergo analysis by whole exome&#xD;
             sequencing or whole genome sequencing during the Pediatric Cardiac Genomic Consortium&#xD;
             2 grant cycle&#xD;
&#xD;
          2. Presence of deleterious mutations (damaging de novo mutations or stringently defined&#xD;
             deleterious missense mutations) identified on sequencing (Cases) OR absence of such&#xD;
             known deleterious mutations (Controls)&#xD;
&#xD;
          3. Males or females, age â‰¥8 years&#xD;
&#xD;
          4. Diagnosis of congenital heart disease&#xD;
&#xD;
          5. Informed consent obtained&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of cardiac transplant&#xD;
&#xD;
          2. A cardiac surgical procedure within 6 months of enrollment&#xD;
&#xD;
          3. Known clinical genetic syndrome, characterized as a monogenic condition with an&#xD;
             identified gene associated with abnormalities of the brain structure or function,&#xD;
             structural heart disease, and potentially other associated features.&#xD;
&#xD;
          4. Presence of CNV known to be clinically pathogenic. Variants will be classified as&#xD;
             pathogenic using accepted types of variant evidence (e.g., population data,&#xD;
             computational data, functional data, segregation data) as detailed in the American&#xD;
             College of Medical Genetics and Genomics &quot; Standards and Guidelines for the&#xD;
             interpretation of sequence variants&quot; (Richards et al, GIM 2015).&#xD;
&#xD;
          5. Overwhelming acquired brain injury, such as a major stroke or severe ischemic injury,&#xD;
             that would overshadow the effect of a genetic mutation on outcome in the opinion of&#xD;
             the center investigator&#xD;
&#xD;
          6. Lack of reading fluency in English or Spanish&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jane Newburger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston Children's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mt. Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.benchtobassinet.org</url>
    <description>Related Info</description>
  </link>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>February 28, 2017</study_first_submitted>
  <study_first_submitted_qc>February 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 3, 2017</study_first_posted>
  <last_update_submitted>August 12, 2020</last_update_submitted>
  <last_update_submitted_qc>August 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Heart Defects, Congenital</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

